The Canadian Life and Health Insurance Association is asking the Ontario government to act cautiously in welcoming private label products under the provincial drug program and allowing them to be interchangeable with other products. Presently, the Ontario Drug Benefit Act doesn’t list private label products as drug products, meaning they’re not eligible for public funding under the drug benefit program. […]
Virtual health-care company Teladoc Health is launching a specialty pharmacy services product aimed at combatting rising prescription drug costs using analytics and medical opinions. “So many people find themselves taking a medication for an extended period of time with limited or no benefit and without the opportunity to fully understand why or learn of alternatives,” said […]
The results of the ongoing renegotiations of the North American Free Trade Agreement could have an impact on how much Canadians pay for their medications in the future, according to one expert. In an article originally published by not-for-profit media outlet the Conversation, Joel Lexchin, an associate professor of family and community medicine at the University of Toronto, pointed out that the […]
High-cost drugs accounted for 41.6 per cent of patented medicine sales in 2017, up from 8.3 per cent a decade earlier, according to the Patented Medicine Prices Review Board’s latest annual report. Federal Health Minister Ginette Petitpas Taylor tabled the report, which also illustrated a rise in the sales of patented medicines in 2017. Sales […]
Lost or damaged prescriptions cost Canadians more than $35 million in productivity, extra travel and time spent filling prescriptions and the potential for adverse health events due to medications that aren’t taken at all, according to a new study by Canada Health Infoway. The study found 40 per cent of Canadians who lost or damaged prescriptions […]
The vast majority (87 per cent) of physicians said the knowledge that a patient has private drug coverage affects their prescribing behaviour, according to a survey by Merck Canada Inc. More specifically, the survey found 26 per cent of general practitioners and 28 per cent of specialists believe this knowledge widens the treatment options available to the patient. Other effects […]
Between 2012 and 2016, Canada’s total private drug claims market increased by a 4.7 per cent compound annual growth rate, according to new research by Innovative Medicines Canada. The analysis, which is based on IQVIA Inc.’s Canadian private drug plan claims database, aims to highlight the key drivers of private drug plan cost growth for the period. “Often the […]
There were almost 4,000 opioid-related deaths in Canada in 2017, according to Health Canada statistics released in June. Meanwhile, in the United States, a new survey by the National Business Group on Health found 60 per cent of large employers had experienced at least one issue stemming from prescription opioid misuse or abuse in the workplace. Forty […]
With an eye toward dismantling the barriers many Canadians face in accessing prescription drugs, the federal government is launching an online consultation process on national pharmacare. The government’s advisory council, introduced in the 2018 budget, is accepting views through an online questionnaire and written submissions. As well, the online platform will include a discussion forum. “Hearing directly from Canadians […]
Orphan drugs represent a significant and growing share of new pharmaceutical entrants in Canada, according to a new report from the Patented Medicine Prices Review Board. At 54 per cent of new pharmaceuticals entering the market in 2015 and 42 per cent in 2016, orphan drugs have seen a significant rise from an average of 33 […]